Edison System histotripsy treatment for enlarged prostate (BPH)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multi-center, single-arm feasibility trial tests the safety of the HistoSonics Edison System to perform histotripsy for men with symptomatic BPH. Subjects will have the index histotripsy procedure, imaging within 72 hours, and clinical follow-up at 30, 90, and 180 days. Key enrollment criteria include age ≥50, I‑PSS ≥15, prostate volume 30–150 mL, Qmax ≤15 mL/s with adequate voided volume, BMI <27, and acceptance of possible loss of ejaculatory function and general anesthesia. Treatment targeting is guided by ultrasound/CT/MR with a required ≥1 cm margin from the rectum.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subject is ≥ 50 years of age.
2. Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
3. Subject is diagnosed with BPH.
4. Subject has a Body Mass Index (BMI) \< 27.
5. Subject has an I-PSS ≥ 15.
6. Subject has a prostate volume \> 30 mL and ≤ 150 mL.
7. Subject has a Qmax ≤ 15 mL/s with a voided volume of ≥ 125 mL during a uroflow test.
8. Subject accepts the potential loss of ejaculatory function.
9. Subject can tolerate general anesthesia. Index-Procedure Imaging Inclusion (Assessed day of procedure)
10. Subject has an adequate acoustic window to visualize the prostate using the HistoSonics Edison System.
11. Target treatment volume is ≥ 1 cm from the rectum as visualized on ultrasound, CT or MR imaging.

Exclusion Criteria:

1. Subject has a life expectancy of less than one (1) year.
2. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
3. Subject has a post-void residual ≥ 150 mL confirmed via ultrasound.
4. Subject has an estimated glomerular filtration rate (eGFR) ≤ 50 mL/min, ≤ 14 days prior to the planned index procedure date.
5. Subject has uncorrectable coagulopathy.
6. Subject has an International Normalized Ratio (INR) value ˃ 2.0, ≤14 days prior to the planned index procedure date.
7. Subject has had a prostatectomy.
8. Subject has acute prostatitis.
9. Subject has a diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome.
10. Subject has had a urinary tract infection (UTI) ≤ 3 months prior to the planned index procedure date.
11. Subject has bladder stones.
12. Subject is catheter dependent or has a history of intermittent self-catheterization.
13. Presence of prostatic calcifications in the planned treatment volume (PTV).
14. Presence of permanent radioactive implants in the rectal wall.
15. Subject has has a major abdominal or rectal surgery that inhibits visualization of the prostate.
16. Subject has undergone prior locoregional therapy (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
17. Subject has planned locoregional therapy 6 months post index procedure (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
18. Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.
19. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
20. In the investigator's opinion, histotripsy is not a treatment option for the subject.
21. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
22. Subject's prostate is not treatable by the System's working ranges (refer to User Guide).

Where it's running

• Prince of Wales Hospital
  Shatin, Hong Kong Recruiting

Study contacts

• Study coordinator: Kelly Erickson
• Email: Kelly.Erickson@histosonics.com
• Phone: 612-965-8895

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sonablate HIFU Registry for Prostate Cancer and BPH

  This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.

  Recruiting Sonablate · Indianapolis, Indiana · NCT07757490

• Tamsulosin alone vs. tamsulosin with tadalafil for troublesome urinary symptoms from enlarged prostate

  This study tests whether adding tadalafil to tamsulosin helps men with BPH see better urinary symptoms and quality of life, using two tadalafil doses over 12 weeks.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07722884

• MRI-DTI look at the urethral sphincter ring and prostate base shape

  This imaging study tests how the male urethral internal sphincter ring appears on MRI-DTI and how it relates to prostate base morphology in men undergoing clinically indicated MRI.

  Recruiting Jiangsu Taizhou People's Hospital · Taizhou, Jiangsu · NCT07694752

• Tamsulosin With or Without Tadalafil for a Trial Without Catheter After Acute Urinary Retention

  This study tests whether adding tadalafil to tamsulosin helps men with a first episode of acute urinary retention due to enlarged prostate pass urine without needing a catheter.

  Recruiting Phase 4 Beni-Suef University · Banī Suwayf, Beni Suweif Governorate · NCT07654413

• Tamsulosin dose change or switch to silodosin before catheter removal in men with BPH-related acute urinary retention

  This trial tests whether continuing tamsulosin, increasing its dose, or switching to silodosin helps men with BPH-related acute urinary retention go without a catheter after seven days.

  Recruiting Phase 4 Beni-Suef University · Banī Suwayf, Beni Suweif Governorate · NCT07650968

• Water Vapor Therapy vs Ejaculation-Sparing Enucleation for Benign Prostatic Hyperplasia

  This study tests whether Water Vapor Thermal Therapy (Rezum) or an ejaculation-sparing enucleation procedure better helps sexually active men with bothersome BPH symptoms.

  Recruiting Beni-Suef University · Banī Suwayf, Beni Suweif Governorate · NCT07648888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.